A dual staining assay for CD44 and BMI-1 demonstrated that there was an elevated expression of CD44 and BMI-1 in the TRAMP prostates which was considerably downregulated by IP6 treatment across all tumor stages. This evidence concerns the gene CD44 and neoplasm.